EE311 Cost-Effectiveness Analysis of Ruxolitinib vs Best Available Therapy for the Treatment of Myelofibrosis in the United States
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.556
https://www.valueinhealthjournal.com/article/S1098-3015(22)00757-4/fulltext
Title :
EE311 Cost-Effectiveness Analysis of Ruxolitinib vs Best Available Therapy for the Treatment of Myelofibrosis in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00757-4&doi=10.1016/j.jval.2022.04.556
First page :
Section Title :
Open access? :
No
Section Order :
10495